Luxury Aesthetics Reimagined: Beauty Factory LV Launches Cutting-Edge Morpheus8 RF Microneedling and Signature Sculpting Treatments
Figure 1: Beauty Factory
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9586/258851_bfms.jpg
A Revolution in Skin Rejuvenation
At the forefront of the launch is the Morpheus8 Advanced RF Microneedling treatment—a breakthrough technology that blends deep microneedling with targeted radiofrequency energy. This premium, minimally invasive service is designed to lift, tighten, and rejuvenate the skin, making it ideal for contouring the jawline, smoothing fine lines, and revitalizing aging or dull complexions.
"This is not your average facial," said Maise Pastrano, a representative for Beauty Factory LV. "With Morpheus8, our clients can achieve sculpted, youthful results with clinical precision—without going under the knife."
Injectable Artistry with Natural Elegance
Complementing the Morpheus8 treatment, Beauty Factory LV now offers precision dermal fillers focused on facial contouring—particularly the chin and lips. These bespoke injectables are tailored to each client's anatomy, enhancing facial harmony while maintaining a natural look.
Recent client transformations—highlighted across the brand's Instagram—showcase the subtle yet striking outcomes from expertly placed fillers, further solidifying Beauty Factory LV's reputation as a go-to for natural refinement.
Botox Beyond Beauty: TMJ & Jaw Slimming Treatments
In addition to cosmetic enhancements, Beauty Factory LV is also offering Botox for TMJ relief and jaw slimming. This innovative, non-invasive treatment helps reduce jaw tension while subtly refining the lower face—merging wellness and aesthetics in a seamless experience.
About Beauty Factory LV
Beauty Factory LV is a boutique medical aesthetics studio based in Las Vegas, specializing in advanced, non-surgical cosmetic treatments that blend science, luxury, and artistry. Known for delivering elite-level care in a serene, client-first environment, the studio continues to raise the bar in modern beauty.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies
DelveInsight's, ' Cystic fibrosis Pipeline Insight, 2025 ' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Cystic Fibrosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Cystic Fibrosis Pipeline Outlook Report Key Takeaways from the Cystic Fibrosis Pipeline Report In July 2025, Enterprise Therapeutics Ltd announced a study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared. In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. DelveInsight's Cystic Fibrosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Cystic Fibrosis treatment. The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Promising Cystic fibrosis Pipeline Therapies such as Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Discover how the Cystic Fibrosis treatment paradigm is evolving. Access DelveInsight's in-depth Cystic Fibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Cystic Fibrosis Clinical Trials and Studies Cystic Fibrosis Emerging Drugs Profile VX-121: Vertex Pharmaceuticals VX-121 and tezacaftor are designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the CFTR protein. VX-561 (deutivacaftor) is a potentiator designed to keep CFTR proteins at the cell surface open longer to improve the flow of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. The triple combination of VX-121/tezacaftor/VX-561 is being developed as an investigational once-daily treatment for people with CF with certain mutations in the CFTR gene. It is currently being investigated in Phase III stage of development. Brensocatib: AstraZeneca Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. The drug is currently being evaluated in Phase II clinical trial to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug. ELX-02: Eloxx Pharmaceuticals ELX-02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX-02 is an aminoglycoside analogue that induces read-through of nonsense mutations through interaction with the ribosome, resulting in the production of full-length functional proteins. The therapy was designated an orphan drug in the US, an orphan medicinal product in Europe, and given fast track designation in the US. ELX-02 is being tested in CF patients carrying least one G542X mutation in two parallel open-label Phase II clinical trials. S-1226: SolAeroMed Inc. S1226 is SolAeroMed's lead therapy. S1226 is formulated to rapidly reopen constricted, mucus plugged airways, and should increase the effectiveness of respiratory drug delivery. The S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways. SolAeroMed is currently conducrting a phase II clinical trial in cystic fibrosis. The Cystic Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment. Cystic Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market Explore groundbreaking therapies and clinical trials in the Cystic Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Cystic Fibrosis Drugs Cystic Fibrosis Companies Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Cystic Fibrosis Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspectives Scope of the Cystic Fibrosis Pipeline Report Coverage- Global Cystic Fibrosis Companies- Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis Pipeline Therapies- Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Cystic Fibrosis drug development? Find out in DelveInsight's exclusive Cystic Fibrosis Pipeline Report—access it now! @ Cystic Fibrosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Cystic Fibrosis: Overview Pipeline Therapeutics Therapeutic Assessment Cystic Fibrosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name: Company Name Drug profiles in the detailed report….. Mid-Stage Products (Phase II) AP-PA02: Armata Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) VX-522: Vertex Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SPL23: SpliSense Drug profiles in the detailed report….. Inactive Products Cystic Fibrosis -Key Companies Cystic Fibrosis -Key Products Cystic Fibrosis - Unmet Needs Cystic Fibrosis - Market Drivers and Barriers Cystic Fibrosis - Future Perspectives and Conclusion Cystic Fibrosis -Analyst Views Cystic Fibrosis- Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
10 hours ago
- CTV News
What to know about soda sweeteners as sugar returns to American Coke
U.S. President Donald Trump teased the announcement last week, but the Coca-Cola Co. confirmed it Tuesday: a cane sugar-sweetened version of the beverage maker's trademark soda will be released in the U.S. this fall. For decades, Coke and the makers of other soft drinks have generally used high fructose corn syrup or artificial sweeteners in their products manufactured in the U.S. But American consumers are increasingly looking for food and drinks with fewer and more natural ingredients, and beverage companies are responding. PepsiCo and Dr Pepper have sold versions of their flagship sodas sweetened with cane sugar since 2009. Coca-Cola has sold Mexican Coke — which uses cane sugar — in the U.S. since 2005, but it's positioned a trendy alternative and sold in glass bottles. Coke with cane sugar will likely be more widely available. Here are some frequently asked questions about the sweeteners in U.S. sodas: What's the difference between cane sugar and high fructose corn syrup? Many consumers know that consuming too many sweets can negatively affect their health, but soda drinkers sometimes debate if either cane sugar or high fructose corn syrup is better (or worse) than the other. The short answer is that it doesn't make a difference, said Marion Nestle, one of the top U.S. nutrition experts and professor emeritus at New York University. High fructose corn syrup is made of the simple sugars glucose and fructose in liquid form. Cane sugar, also known as sucrose, is made of glucose and fructose bonded, but quickly split, Nestle explained. Both are still sugars, with about the same amount of calories. Whether a can of Coca-Cola contains one or the other, it will still be a sugary drink with about the same amount of calories and the same potential to increase well-documented health problems from obesity and diabetes to tooth decay. Why did soda companies switch from using sugar to high fructose corn syrup? High fructose corn syrup costs less. According to price data from the U.S. Department of Agriculture, the wholesale price of HFCS-55, the type of corn syrup most commonly used in beverages, averaged US49.4 cents per pound last year. The average wholesale price of refined cane sugar was 60.1 cents per pound, while the average wholesale price of refined beet sugar was 51.7 cents per pound. But high fructose corn syrup has advantages beyond price. According to a 2008 paper in the American Journal of Clinical Nutrition, high fructose corn syrup is more stable than sugar when added to acidic beverages, and it can be pumped directly from delivery trucks into storage and mixing tanks. Why is high fructose corn syrup less expensive that sugar? Tariffs are one reason. The U.S. has had barriers on sugar imports almost back to its founding; the first went into place in 1789, according to the Cato Institute, a think tank that advocates free markets. Since the passage of the Farm Bill in 1981, the U.S. has had a system in place that raises duties on sugar once a certain amount has been imported. The U.S. also has domestic production controls that limit supplies, keeping prices higher. But high fructose corn syrup is also cheaper because of the federal government's billions of dollars in subsidies for corn farmers. Loans, direct payments, insurance premium subsidies and surplus crop purchases all lower farmers' costs – and the price of the corn they grow. Are sugar replacements used in diet sodas safe? While cutting back on added sugars has documented benefits, replacing them with artificial sweeteners is complicated, too. Coca-Cola Zero Sugar, introduced in 2017, uses the artificial sweetener aspartame and the natural sweetener stevia in its recipe. But research suggests that aspartame may be linked to cancer. In 2023, a committee for the World Health Organization determined that aspartame should be categorized 'as possibly carcinogenic to humans.' While that doesn't mean that diet soda causes cancer, the scientific committee concluded that there may be a possible link between aspartame and liver cancer, and that the issue should be studied further. The U.S. Food and Drug administration disagreed with the WHO panel, citing 'significant shortcomings' in the research that backed the conclusion. FDA officials noted that aspartame is one of the most studied food additives and said 'FDA scientists do not have safety concerns' when it is used under approved conditions. Stevia, a plant-based sweetener, appears to be 'a safe choice,' according to the Center for Science in the Public Interest, an advocacy group. Durbin reported from Detroit. Aleccia reported from Los Angeles. Dee-ann Durbin And Jonel Aleccia, The Associated Press
Globe and Mail
11 hours ago
- Globe and Mail
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. 'John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations,' said Mike Druhan, MedX President, Dermatology Services. 'His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.' 'Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,' said John Gevisser. 'As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.' While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. 'The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,' said Ken McKay, Chairman of the Board. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy ® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit:
